Group items tagged

Pharmacists are a vital member of the multidisciplinary team (MDT) supporting older people to manage their pain. The pharmacist is uniquely positioned to holistically review drug interactions and potential risks associated with each patient's medication and has the expertise to suggest alternative treatment options to reduce the risks associated with polypharmacy or unwanted side effects caused by other medications. Chronic pain The International Association for the Study of Pain defines pain as an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Although universally experienced by everyone, the perception of pain is a deeply personal experience influenced by biological, psychological, and social factors, and constitutes an essential behavioural feedback mechanism aimed at protecting us from harm. Pain may be perceived as either acute or chronic. Chronic pain, defined as pain that persists longer than the normal healing time, constitutes a substantial healthcare burden, affecting approximately 20 per cent of people worldwide and accounts for 15-20 per cent of physician consultations. Chronic pain is often associated with disrupted mood and sleep, substance misuse and other chronic conditions. Additionally, comorbidities of chronic pain may also lead to complex medication regimens that increase the risks of adverse drug interactions and unwanted side effects.

A new report published today (June 29) by the think tank Policy Exchange highlights key role for community pharmacy in management of primary-secondary care interface. The report called Medical Evolution has received cross-party support. It says an equivalent of 15 million GP appointments per year are spent dealing with issues managing care between GP practices and hospitals. Research from the think tank also finds 150,000 people could be on 'hidden' waiting lists (where a patient has been referred by a GP for further treatment, but not included on official hospital waiting lists). On the eve of the NHS Long Term Workforce Plan, the report calls for the development of 'interface specialists' - which could be undertaken by doctors, nurses or community pharmacists to enable them to work more routinely across settings and to strategically plan interface working.

The Pharmaceutical Services Negotiating Committee (PSNC) and NHS England have agreed that community pharmacy contractors will have to participate in one mandatory national health campaign. This campaign on weight management commenced from Tuesday (03 January) and will run until Sunday (29January). PSNC said: "Pharmacies can be required to participate in up to six health campaigns at the request of NHS England per year (1st April to 31st March). Pharmacies will be involved by displaying and distributing leaflets provided by NHS England. In addition, pharmacies are required to undertake prescription-linked interventions on major areas of public health concern, such as encouraging smoking cessation. "Contractors can order pharmacy specific posters, wallet cards ('info' cards with a QR code signposting people to the Better Health website and free tips and tools to lose weight) and a dispenser for these cards on the Campaign Resource Centre website. A guidance leaflet to support community pharmacy teams' conversations with patients is also available," said PSNC.

Alliance Healthcare, the UK's largest pharmaceutical wholesaler, announced today (December 7) the appointment of Marie Evans as its new managing director. Evans, who is the current commercial and category director of the firm, will report to Juan Guerra, Alliance Healthcare's senior vice president and managing director of International Wholesale. Commenting on the new appointment, Guerra said: "The last 18 months has shown just how important wholesale and distribution is to the NHS and I am so excited to welcome Marie to her new position at this critical time. "Her experience and leadership will be key as we continue to evolve our services in response to the changing needs of pharmacy, the health service, and industry."

Skelmersdale-based online pharmacy Chemist4U has secured a £12 million investment from Pitalia Capital, an equity investment company led by Anil Pitalia. Chemist4U is part of JCCO Healthcare, which also houses the weight management platform myBMI. Anil Pitalia is a health enthusiast, who heads SpaMedica, a company providing cataract surgery to the NHS. This investment will propel the group's expansion, with John Davies, Managing Partner of Pitalia Capital, joining the board, the company said. Moreover, it will facilitate the extension of services by myBMI in the realm of weight management. "Our goal is for Chemist4U to emerge as one of the largest NHS dispensing facilities in the country, while also providing vital support to our partners through our rapidly expanding outsourced dispensing services division," said said James O'Loan, Chief Executive Officer of both Chemist4U and myBMI, who joined Chemist4U as a superintendent pharmacist in 2012 before becoming CEO in 2018. Meanwhile, Anil Pitalia, Head of Pitalia Capital based in Bolton, cited the compelling growth potential as the driving force behind his investment in Chemist4U's next-day medicine delivery service.

Consumer health company Haleon, formerly known as GSK, claims that pain's emotional and life impact has grown by nearly 25 per cent in the past decade. The company has launched a campaign #ListenToPain to personalise patients' pain management through a series of practical tools and resources. The campaign was introduced on 28 September which focused on enabling the HCPs to maximise their time with patients and understand their pain experience - providing them with an effective treatment plan. The new data has been obtained through the fifth edition of the Haleon Pain Index (HPI). This social study measured the impact of individuals' everyday lives, their health, their feelings, their emotions, motivations and behaviours. They have spoken to more than 87,000 people around the world since their first edition in 2014 - HPI 1 (The State of Pain), which later progressed over the years from HPI 2 (Impact of Pain) in 2017, then HPI 3 (Managing Pain) in 2018, to HPI 4 (Treatment Journey), and finally HPI 5 (Pain and Inclusivity) in 2023.

If you have recently been diagnosed with hearing loss, you may be feeling overwhelmed and unsure of what to do next. You are not alone - millions of people around the world are living with hearing loss. The good news is that there are many resources available to help you learn how to manage your condition and live a full life. In this blog post, we will discuss some of the most common issues that people with hearing loss face and provide tips on how to handle them. HANDLING ISSUES FROM HEARING LOSS - HOW TO DO IT PROPERLY Hearing loss is certainly a difficult obstacle to face in life, but it doesn't have to stop you from living a full and rich life. Of course, hearing loss comes with its own set of unique challenges, but there are ways to manage them. From learning what hearing aids are the best for you to communicate with loved ones, to the different types of therapies available, we're here to help you find the answers you need. Generally speaking, there are four main issues that people with hearing loss face; Isolation, communication difficulties, feeling overwhelmed and frustrated, and depression. Unfortunately, each of these "consequences" will likely get worse if hearing loss is not managed early on. Here are some tips on how to handle each one:

The National Pharmacy Association (NPA) and BeWell are working together to help provide efficiencies and productivity that address the growing pressures within community pharmacy. BeWell's Pharmacy Management Platform provides robust solutions that include Patient Relationship Management, Omnichannel Communications and Engagement, Services and Bookings Management, access to patient records, NHS Login supported Patient Application, and repeat prescription capabilities for Pharmacy Website and Patient App that include integrations with Surgery Online Services. This single interoperable platform is also integrated with pharmacy PMRs, connecting back office and administrative functions with front-of-house digital patient experiences. In line with the NPA's vision, BeWell has taken a leading role in formulating a unique ecosystem of pharmacy partners uniting marketing agencies, PGD-based service providers, and delivery method partners - integrating their capabilities within the BeWell platform.

The General Pharmaceutical Council (GPhC) has initiated the evaluation of its five-year strategy for changing the way it manage concerns about pharmacy professionals. It has urged people to share their experience of fitness to practice. The evaluation will look at how the strategy has improved the experience of people involved in fitness to practice (those who raise concerns, professionals, witnesses etc.); impacted the culture amongst pharmacy professionals and their attitudes to openness and honesty; improved the process and made it fairer and changed perceptions of fitness to practice. The first phase of the evaluation process will take place from July to September 2023. The council said: "We are committed to making our ambitions a reality for the benefit of everyone involved and your contribution will help us to make sure patients and the public continue to be protected while being fair to pharmacy professionals." In June 2021, GPhC published its five-year strategy- Managing concerns about pharmacy professionals: Guided by its 2030 vision and commitment to equality, diversity and inclusion, the strategy outlines a programme for change.

Living with diabetes can be managed by proper medication. However, you may have questions regarding the medications available to you. Here, we will take a closer look at two medications, Ozempic and Saxenda, so that you can see how these medications can impact your health. A CLOSER LOOK AT DIABETES Diabetes can be divided into two categories, type 1 diabetes (T1D) and type 2 diabetes (T2D). Type 1 diabetes is an autoimmune disorder and is commonly diagnosed in children. Individuals with T1D require lifelong insulin treatment to manage their diabetes. Type 2 diabetes is diagnosed later in life due to genetics, lifestyle, and other risk factors. Unlike T1D, there are numerous treatment options other than insulin therapy to manage type 2 diabetes. GLP-1 RECEPTOR AGONISTS A common drug class used to treat type 2 diabetes is glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists work by lowering blood glucose and slowing gastric emptying. Benefits of using a GLP-1 receptor agonist include: weight loss, atherosclerotic cardiovascular disease (ASCVD) benefits, lowering A1C values, and chronic kidney disease (CKD) benefits with little risk of hypoglycemia. Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, weight loss, and injection site reactions. GLP-1 receptor agonists should not be used in patients with a personal or a family history of medullary thyroid cancer.

Diabetes affects over 537 million people worldwide; by 2045, this is estimated to increase to 783 million. [1] With the growing prevalence of diabetes, it's even more important to utilise all options to support people with diabetes (PwDs) in managing their daily life with diabetes. Where do PwDs most often access healthcare support? On average, PwDs visit the pharmacy three-to-eight times more than the general population to obtain medicines and testing supplies.[2] It is clear that pharmacists play an integral role in empowering the self-management needs of PwDs beyond the traditional role of supplying medicines. This relationship, however, may be underutilised. Research suggests there is a lack of broad recognition of pharmacists as a key source of diabetes care, and that resource constraints - particularly following the COVID-19 pandemic - can interfere with patient education provision and training.[3,4] Furthermore, the circumstances and role of the pharmacy vary, nationally and internationally. At Roche Diabetes Care we would like to shine a light on the increasing value of community pharmacists as important figures in the well-being of PwDs.

Numark is set to launch a large-scale broadcast campaign to promote its Hey Pharmacist repeat prescription service on May 22. The new campaign introduces, 'Repeat prescriptions. Made simple,' with a set of three TV adverts that feature three different heightened-reality scenarios. In each advert, the hero discovers they have forgotten to order their repeat prescription at a less than ideal time but thanks to Hey Pharmacist, a few taps later their problems are solved. The adverts highlight how managing your repeat prescriptions has never been quicker or simpler in a tongue-in-cheek, comedic tone. The campaign - which incorporates national broadcast and SkyAdSmart TV alongside digital, social, and in-store campaigns across England - promotes the Hey Pharmacist app which provides Numark members in England with an end-to-end online repeat prescription proposition, helping them deliver a best-in-class digital capability which highlights the benefits for patients who choose to collect their medication from their local Numark pharmacy. Jeremy Meader, managing director of Numark, commented: "It is very exciting to see our first TV campaign go live. The creative does a brilliant job in bringing to life the benefits of Hey Pharmacist, highlighting how easy and effortless managing prescriptions can be. We look forward to assisting more everyday heroes and supporting our members in showcasing this exciting digital proposition to a larger audience."

A pharmacist in a leading independent pharmacy chain shares his myth-busting Ramadan advice on managing health and the use of medication while fasting. While the holy month means total fasting in terms of oral consumption, it's still ok, says Ifti Khan, superintendent pharmacist at Well Pharmacy, to have vaccinations and blood tests and to use eye drops or other medical items that are not ingested through the mouth. It's also important for people to keep taking their prescribed medication over the Ramadan period. Anyone who is concerned should speak to their pharmacist about whether they can take their medicine at different times, as stopping it could have serious consequences. Mr Khan, who will be observing Ramadan himself, said: "Confusion can sometimes arise when it comes to medication and managing health conditions whilst fasting", adding it is important for patients to keep managing health during Ramadan. Having injections or vaccinations is fine, as are blood tests, using eye or ear drops, and using anything that patients don't consume orally - so nicotine and other transdermal patches, pessaries and dialysis, for example. It's also ok to eat and drink as a result of a condition which causes forgetfulness.

Amidst the pervasive prevalence of pain, with 93% of the global populace experiencing it annually and 1 in 3 enduring daily discomfort, there persists a reluctance to address and treat pain proactively. This leads to a heightened burden of suffering among individuals. Join us for an enlightening 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with vital strategies to comprehend, manage, and alleviate pain in patients' daily lives. Delve into topics such as the pharmacist's evolving role, understanding pain assessment, and Haleon's #ListenToPain campaign, aimed at fostering better patient conversations. Tailored for pharmacists in GB dealing with acute or chronic pain, this webinar promises to enhance patient care and contribute positively to their well-being. Don't miss out on this opportunity to make a meaningful difference. Register now to secure your spot at this impactful event!

Amidst the pervasive prevalence of pain, with 93% of the global populace experiencing it annually and 1 in 3 enduring daily discomfort, there persists a reluctance to address and treat pain proactively. This leads to a heightened burden of suffering among individuals. Join us for an enlightening 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with vital strategies to comprehend, manage, and alleviate pain in patients' daily lives. Delve into topics such as the pharmacist's evolving role, understanding pain assessment, and Haleon's #ListenToPain campaign, aimed at fostering better patient conversations. Tailored for pharmacists in GB dealing with acute or chronic pain, this webinar promises to enhance patient care and contribute positively to their well-being. Don't miss out on this opportunity to make a meaningful difference. Register now to secure your spot at this impactful event!

Kanabo Group plc, a medical cannabis research and development company, has entered into a partnership with City Dock Pharmacy in London to introduce a walk-in clinic for pain management. The pain clinic will cater to patients who are eligible for alternative therapies (when traditional treatments have failed to deliver improvements), and will offer specialised medicines, including medicinal cannabis. When it opens, the new facility at City Dock Pharmacy in Wapping will become the UK's first walk-in clinic for pain management, but it will also deliver appointment-related services, the companies said. The partnership is part of the London-based company's wider ambition to extend its reach into physical pharmacies throughout the UK, and its plans to replicate this model across other pharmacies.

The Challenges There cannot be anyone working in or with community pharmacy that either feels or sees the pain that emanates from the current operating climate. Pharmacy closures; increased workload and operating costs; increased patient and commissioner expectations; and, more fundamentally, an inadequate, undervalued and poorly structured remuneration and reimbursement contractual framework. As important as they are, we will not focus on these points here as they are not in the control of pharmacy owners and managers. They are the responsibility of those organisations that represent them at a national and local level who must deliver a better outcome as difficult as that may be. However, there are matters which are in the control of pharmacy owners and managers. These include their premises, their team, their systems and processes, their relationships with other healthcare providers and the broader community, their NHS and private service offer, and how they promote and deliver them to give the best patient experience. In order to create the head space to develop and implement a business plan, pharmacy owners and managers must make time to work on their business as well as in it. Then it requires the capacity and capability within their team to deliver the services and that excellent patient experience.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes on Tuesday (27 June). "There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM)," said DHSC. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to normal until at least mid-2024. Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative treatment options.

The British Generic Manufacturers Association (BGMA) has elected Matthew Salzmann, UK Country Manager at Viatris, as its new Vice-Chair with immediate effect. He will replace the current chair of the BGMA, Diane DiGangi-Trench, who is the UK country head for Sandoz. Salzman, who is originally from Australia, has served approximately 1 billion patients worldwide last year as the UK Country Manager at Viatris, a global pharmaceutical company operating in 165 countries. In his role as BGMA Vice-Chair, Salzmann would focus on working in partnership with key stakeholders - the NHS, healthcare professionals, policy makers, clinical societies, patient associations, academia - to ensure access to affordable and sustainable medicines for patients and the NHS.

Leo Pharma, one of the leaders in medical dermatology, has appointed Kasper Künzel as Interim Vice President and General Manager for its UK and Ireland business. Kasper is an established leader within Leo Pharma, having previously been Vice President, IPO Preparedness Office, at Leo Pharma in Denmark. Kasper brings over 17 years of pharmaceutical experience, previously taking on local and global leadership positions across Leo Pharma in functions including R&D, Finance and Commercial. Having first joined Leo Pharma in Denmark in a financial function, his previous roles include General Manager in South Korea, Vice President of Corporate Transformation, and Director of R&D Business Finance He commented: "I am delighted to join the Leo Pharma UK and Ireland team and continue to build on the company's strong heritage in these markets. The UK and Ireland team are committed to the Leo Pharma values as a leader in medical dermatology, and I'm looking forward to all we can achieve together this year.